Our mission is to develop safe, cost-effective gene therapies that modulate the immune system to address serious unmet treatment needs.
Gene therapy for treating rheumatoid arthritis (RA)
Our lead agent is WYV-RA, a gene therapy that treats RA by upregulating CTLA4 in target tissues, and downregulating TNF so that it is not excreted by the target tissues.
- First randomized clinical trial in RA patients currently in the planning stages.
Gene therapy for treating viral pneumoniae, including coronaviruses such as COVID-19
Our second agent is WYV-RV, a gene therapy that treats viral pneumoniae by upregulating siRNA against the virus in target tissues.
- First randomized clinical trial in COVID-19 patients currently in the planning stages.
Gene therapy for treating TLR3-negative tumours
Our third agent is WYV-ONC, a gene therapy that treats cancer by upregulating TLR3 in target tumours and overcomes immunotherapy treatment resistance when used in combination with immunotherapies such as checkpoint inhibitors.
- First clinical study in cancer patients currently in the planning stages.
Founded in 2017, Wyvern Pharmaceuticals Inc. is a privately held biopharmaceutical company headquartered in Calgary, Canada.
Our executive team brings together decades of experience in drug development and taking new therapies to market. Together, we aim to deliver meaningful quality of life and lifespan extension benefits to patient populations with serious unmet treatment needs.
We are beginning this journey with a proprietary gene therapy platform to safely and effectively treat serious illnesses, including autoimmune disorders, cancer and infectious diseases.